Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026)
Akebia Therapeutics (AKBA) reported Cash from Investing Activities of -$62000.0 for Q1 2026, down 140.26% year-over-year from $154000.0 in Q1 2025, and up 99.21% quarter-over-quarter from -$7.9 million in Q4 2025.
Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 13 years of Cash from Investing Activities data on file, last reported at -$62000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$62000.0, down 140.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.1 million (down 6828.93% YoY), and the FY2025 annual result was -$7.9 million, down 23918.18% from the prior year.
- Cash from Investing Activities grew to -$62000.0 in Q1 2026 per AKBA's latest filing, from -$7.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $154000.0 in Q1 2025 and troughed at -$7.9 million in Q4 2025.
- A 4-year average of -$903888.9 and a median of -$62000.0 in 2026 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 100.57% in 2022, then tumbled 393750.0% in 2025.
- A 4-year view of Cash from Investing Activities shows it stood at -$114000.0 in 2022, then soared by 98.25% to -$2000.0 in 2024, then plunged by 393750.0% to -$7.9 million in 2025, then jumped by 99.21% to -$62000.0 in 2026.
- Business Quant data shows AKBA's Cash from Investing Activities at -$62000.0 in Q1 2026, -$7.9 million in Q4 2025, and -$77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Akebia Therapeutics | 235.00 Mn | 72.40 Mn | 41.25 Mn | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -7.88 Mn |
| Dec 31, 2025 | -7.88 Mn |
| Sep 30, 2025 | -77,000.00 |
| Sep 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Jun 30, 2021 | 20.00 Mn |
| Jun 30, 2021 | 20.00 Mn |